Important differences exist in how colorectal cancer is detected, but not necessarily in how it is treated once detected. Significant improvements have occurred in colorectal cancer treatment through time, yet these improvements may not be distributed equally across all racial groups. Previous research has also found Black-White differences in stagespecific colorectal cancer survival rates, suggesting disparities in the management of cancer. [8] [9] [10] In this article, we assessed whether differences in stage-specific colorectal cancer survival rates reflected racial differences over 4 decades. In doing so, we adjusted for differences in incidence and screening, focusing instead on the management of tumors once they are found. Racial disparities are likely a product of a broad set of social, biological, and environmental factors. By observing changes in stage-specific mortality over time, rather than statically at a cross-sectional moment, we may develop a better understanding of how these factors have contributed to increased racial disparities.
METHODS
To estimate overall colorectal cancer mortality rates, we used death counts from Mortality Multiple-Cause-of-Death Data files, which contain information from US death certificates transmitted to the National Center for Health Statistics between 1960 and 2005. Pertinent information includes date of death, gender, race, age, and cause of death. We identified deaths from colon cancer and rectal cancer by International Classification of Diseases versions 7, 8, 9, and 10 coding. Large-scale assessments comparing hospital medical records and death certificates have found colorectal cancer death reporting to be highly accurate. 11, 12 We used decennial census counts and annual intercensal estimates of the study population by age, gender, and race to estimate exposure to the risk of death. Mortality rates were defined as the ratio of death counts to exposure by age, gender, race, and year. For each year, we calculated the crude colorectal cancer mortality rate and then standardized it to a common age composition (arbitrarily chosen as the White male age distribution in 1990) to allow comparison across gender, race, and time. 13 We used the Kaplan-Meier method to estimate survival curves in order to compare observed survival between Blacks and Whites and among stages of colorectal cancer for a given gender and decade of diagnosis.
To account for sampling uncertainty in the SEER data, we applied the bootstrap resampling procedure. In 1000 random samples, original data were replaced to estimate confidence intervals in our outcomes of interest. 14 The bootstrapped sample sizes were equal to the original sample size (N SEER =536 277 statistical interaction of race and decade of diagnosis. We graphically and statistically tested the proportional hazards assumption and found no strong evidence in support of nonproportionality for the covariates specified, which suggests a Cox model as an appropriate model for these data. We used R version 2.9.2 (R Project for Statistical Computing; available at http:// www.r-project.org) for all statistical analyses. Figure 1 depicts overall colorectal cancer mortality rate trends and reveals 2 results. First, both White men and women historically experienced higher colorectal cancer mortality rates than did their Black counterparts. The racial crossover from higher to lower mortality rates occurred around 1970 for women and 1979 for men. Second, progress against overall colorectal cancer mortality in the last 45 years Stage-specific colorectal cancer survival rates were lower for Blacks than for Whites in each of the last 4 decades. Figure 2 shows, as an example, women aged 60-64 years who were entered into the SEER Registry during the 1990s. The survival rate of Black women who had localized and regional colorectal cancer was significantly lower compared with White women. For distant cancer, the survival rate among Blacks was significantly lower after 2 years. We found similar patterns in women and men aged 50 years and older in all 4 decades. In general, the hazard of death was greater for Blacks than for Whites for all age groups, all decades, and both genders.
RESULTS
Hazard ratios (which reflect excess mortality of Blacks over Whites) increased across decades as shown in Figure 3 . In other words, we found a positive interaction of race and time, which indicated worsening survival rates in stage-specific colorectal cancer for Blacks. In the 1970s, the hazard of death was 1.11 times greater (95% CI =1.07, 1.17) for Black patients compared with White patients of the same age group, gender, and stage at diagnosis. The disparity increased consistently over the next 3 decades. The hazard of death for Black patients was 1.22 times greater (95% CI =1. 19 
DISCUSSION
This study has 3 important findings. First, Black patients have consistently worse stagespecific colorectal cancer survival rates than White patients, an effect found for both men and women, across all age groups, and for localized, regional, and distant stages of the disease. Second, the gap between survival rates for Blacks and Whites is widening over time-an effect largely attributable to declining mortality among Whites over the past 4 decades but also to far less improvement in stagespecific survival rates for Blacks during the same period. Third, racial differences in stagespecific survival are associated with differences in life expectancy among Black and White colorectal cancer patients.
Our results are consistent with previous population-based and multiple institutionbased studies that observed stage-specific racial disparities in colorectal cancer mortality for specific time periods. In their study of patients enrolled in the National Cancer Institute Black-White Cancer Survival Study, Mayberry and colleagues found the hazard of death for Blacks with colorectal cancer was 1.00-1.45 times higher than for Whites, conditional on age, gender, and cancer stage. 15 characteristics. 16 To our knowledge, our study is the first to demonstrate that the hazard of death for Blacks is growing over time, across both genders, and all disease stages. The predominant and enduring trends in our analyses reveal substantial and increasing advantages in stage-specific colorectal cancer survival for Whites. Differences in stagespecific survival may result from differences in (1) accuracy of staging, (2) tumor biology, (3) competing mortality, or (4) treatment. First, if Black patients are more consistently understaged than White patients (for example, if tumors in Blacks are more likely to be classified as localized even though the tumors are in fact regional), those misclassifications could contribute to observed racial disparities in stagespecific survival. Second, if colorectal cancer among Black patients is more aggressive than among White patients, we would expect the racial differences in stage-specific survival that we observed; however, there appears to be strong evidence against such a possibility. 5, 17, 18 Black patients are more likely than White patients to have more proximal colorectal tumors 19 and to have proximal tumors present at more advanced stages, 20 but these differences are generally attributed to differences in detection rather than biology. More generally, if biologic differences were to explain our findings, we would have to postulate that these biologic differences have been increasing in the last 4 decades to account for the widening disparity we observed over time. Third, competing mortality from comorbid conditions could contribute to observed differences in stage-specific survival rates. Differences in mortality rates between Blacks and Whites have generally increased through time, although there are exceptions such as deaths from influenza and pneumonia. 21 We do not know whether Black colorectal cancer patients experience higher mortality from comorbid conditions as compared with that of similarly staged White patients. We observed a very small advantage in life expectancy among White patients who have distant metastatic colorectal cancer compared with similarly staged Black patients, which suggests there are not any large differences in competing mortality from comorbid conditions. A similar finding and conclusion were noted by Marcella and Miller. 16 Fourth, differences in type of treatment recommended, completion of treatment, and post-treatment surveillance may be important factors contributing to rising stage-specific survival disparities. Race itself may not drive the widening survival gap for stage-specific colorectal cancer. Rather, race likely serves as a confounding variable. Numerous literatures spanning sociology, economics, health policy, and medicine argue that race may be a proxy for income and wealth, educational attainment, employment, residential segregation, medical insurance, access to health care, characteristics of the hospital in which care occurs, home ownership, region of the country, and marital status. Stagespecific colorectal cancer survival may be more proximally related to these socioeconomic covariates, rather than to race. For example, Marcella and Miller found excess hazard of death among Blacks was reduced after adjusting for several socioeconomic characteristics and for stage, age, and gender. 16 Racial and socioeconomic disparities in overall and stage-specific survival have also been observed in lung, 29 33 Their analysis carefully considered the validity of national death data and attribution bias as possible explanations. Yet given the magnitude of the observed racial crossover, they argue that cigarette smoking, migration, and occupational patterns (especially industrial employment), as well as environmental factors, must also be leading contributing factors. We acknowledge several limitations of our study. First, variability and biases in death certificate data, especially cause of death and age at death, may distort temporal patterns in mortality rates. Assessments that compare hospital diagnosis and cause of death listed on the death certificate have found detection and confirmation rates exceeding 93% for colorectal cancer. 11, 12 However, our results could be biased if the accuracy of assessments of cause of death varies by race or across decades. Second, the SEER Registry does not capture the entire US population. Our results may be biased to the extent that the SEER Registry fails to represent more general US trends. Third, because of the need to compare data from 1960 and later, we used the broader cancer stage categories of localized, regional, and distant rather than the more exact criteria of the American Joint Committee on Cancer. However, the broader categories remain clinically meaningful in predicting both treatment and outcome. Our results suggest large and growing differences in stage-specific colorectal cancer mortality rates for Blacks and Whites. Because racial disparity is unlikely to be a product of differences in the accuracy of staging, tumor biology, or competing mortality, racial disparity seems most likely to be a product of differences in access to care or the quality of that care. The existence of racial differences in colorectal cancer management demands attention, and the increase of those disparities over the past several 4 decades should make this a priority. j
